A real-world analysis of adherence barriers and reasons for non-persistence in patients receiving intravitreal therapy with anti- vascular endothelial growth factor therapy –a patient and physician survey in germany
- Conditions
- H35.0H35.30Background retinopathy and retinal vascular changes
- Registration Number
- DRKS00032513
- Lead Sponsor
- F. Hoffmann-La Roche Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting stopped after recruiting started
- Sex
- All
- Target Recruitment
- 55
The patient has been diagnosed with nAMD and/or DME
The patient is at least 18 years of age (DME)/ the patient is at least 50 years of age (nAMD)
The patient has started IVT with anti-VEGF therapy in routine clinical practice =5 years ago
The patient is currently receiving (or received at the time of last injection) an anti-VEGF agent approved in Germany for the respective indication (nAMD/DME)
The patient receives all care in relation to their eye disease at one center/practice (no referral by another practice/center)
To the knowledge of the treating physician, the patient has not previously received and is not currently receiving IVT with anti-VEGF therapy at another center/practice
The patient is capable of participating in a 45-minute telephone interview in German language
Basic clinical information about the patient and his/her care is available in the patient charts (minimum 6-month medical records).
There are no explicit exclusion criteria.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To describe barriers to IVT adherence experienced by nAMD and DME patients and to investigate and quantify whether injection frequency exert an influence on patients’ adherence and persistence to IVT. To elicit reasons for non-persistence
- Secondary Outcome Measures
Name Time Method To explore physician’s awareness and understanding of adherence and persistence and to shine light on the practical hurdles faced by treating ophthalmologists.<br>